Artiva Biotherapeutics

Edit info

Founded: 2019

Location: San Diego, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: B-cell malignancies (Fast Track)

Drug types: ONC

Lead product: AB-101 (partner: Affimed)

Funding: $120M B Feb 2021; $78M A Jun 2020

artivabio.com

linkedin.com

job board

Drug notes:

Also Clin0 Hodgkin's lymphoma/T-cell lymphoma, Clin0 multiple myeloma; AB-201 Clin1 HER2+ cancers; AB-203 RD/Cln0 multiple myeloma; AB-205 RD/Clin0 T-cell lymphoma; AB-MK-001 RD/Clin0 solid tumor; AB-MK-002 RD/Clin0 solid tumor

About:

Artiva Biotherapeutics is developing immune cell therapies to treat cancer. Natural killer (NK) cells are part of the innate immune system that are the first line of defense for the recognition and destruction of cancerous cells. Artiva is engineering NK cells using their AlloNKTM platform to enhance their targeting and activity. Specifically, Artiva is focused on generating off-the-shelf, allogeneic NK cell therapies with improved performance to treat hematologic cancers or solid tumors. The platform is designed to deliver scalability, quality and cryopreservation to support their mission of creating a pipeline of safe, effective, versatile and accessible products. Artiva’s lead program is in Phase 1 trials for B-cell malignancies.